Celcuity Investor Relations Material

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company develops Tarcelisib, a small molecule inhibitor of protein kinase ribosomal S6 kinase beta (S6K1) for the treatment of solid tumors. Its clinical programs include Phase II Soliloquy study for rTRT in hormone refractory prostate cancer and Phase I Celcuity 9088 study investigating Tarcelisib as a treatment for endometrial cancer.